Recommendations for the use of etanercept in psoriasis: A European dermatology expert group consensus

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 8, 2006, Pages 988-998

  Boehncke, W H ^a   Brasie, R A ^b   Barker, J ^c   Chimenti, S ^d   Dauden E ^e   De Rie, M ^f   Dubertret, L ^g   Giannetti, A ^h   Katsambas, A ⁱ   Kragballe, K ^j   Naeyaert, J M ^k   Ortonne, J P ^l   Peyri J ^m   Prinz, J C ⁿ   Saurat, J H ^o   Strohal, R ^p   Van De Kerkhof, P ^q   Sterry, W ^r  

^a GOETHE UNIVERSITY   (Germany)

^b ANKARA UNIVERSITY   (Turkey)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g SAINT LOUIS HOSPITAL   (France)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ UNIVERSITY OF ATHENS   (Greece)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

^l CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^o GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^p Federal Academic Hospital Feldkirch   (Austria)

^q RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^r CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Biological therapy; Consensus; Etanercept; Psoriasis

Indexed keywords

CYCLOSPORIN A; ETANERCEPT; ETRETIN; METHOTREXATE;

ACRODERMATITIS; ARTICLE; BIOLOGICAL THERAPY; CHILD CARE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DERMATOLOGY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LABELING; DRUG SAFETY; DRUG UTILIZATION; DRUG WITHDRAWAL; EUROPE; EVIDENCE BASED MEDICINE; HEALTH STATUS; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL SPECIALIST; PATIENT MONITORING; PATIENT SELECTION; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; QUALITY OF LIFE; REMISSION; TREATMENT FAILURE; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; WELLBEING;

EID: 33747330817     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01707.x     Document Type: Article

References (41)

1. Enbrel® Summary of Product Characteristics. Wyeth Europa Ltd, Maidenhead, 2005.
2. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632.
3. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
4. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
5. Tyring S, Rosoph L, Toth D, Zitnik R. A 2-year Phase 3 Study of Safety and Efficacy of Etanercept 50 mg Twice Weekly in Patients with Psoriasis: Results from the 3-month Double-blind Period. Presented at the American Academy of Dermatology, February 18-22, 2005, New Orleans, Louisiana. Abstract P2700.
6. Linstone AL, Furoff M. The Delphi method. Techniques and Applications. Addison-Wesley Company, Massachusetts, 1975.
7. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
8. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. Br J Dermatol 1999; 141: 185-191.
9. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9: 169-180.
10. Young Park J, Hyun Rim J, Beom Choe YII, Youn J. Facial psoriasis: comparison of patients with and without facial involvement. J Am Acad Dermatol 2004; 50: 582-584.
11. Sampogna F, Gisondi P, Melchi CF et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-599.
12. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356: 385-390.
13. Maxtrex® Summary of Product Characteristics. Pharmacia Ltd, 2004. Available from: http://emc.medicines.org.uk/ [accessed August 2005].
14. Gottlieb A, Grekin S, Maloney JM, Xia HA, Stevens SR. Preliminary Results of EDUCATE, a Multicenter, Community-based, Open-label study of the Effect on Skin and Joint Disease in Patients with Psoriatic Arthritis. Presented at American Academy of Dermatology, February 18-22, 2005, New Orleans, Louisiana. Abstract P2780.
15. Lebwohl M, Gottlieb A, Goffe BS, Jahreis A. Etanercept in Psoriatic Arthritis: Sustained Improvements in Skin and Joint Disease and Inhibition of Radiographic Progression at 2 Years. Presented at the American Academy of Dermatology, February 18-22, 2005, New Orleans, Louisiana. Abstract P2753.
16. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272.
17. Neoral® Summary of Product Characteristics. Novartis Pharmaceuticals, UK Ltd, 2005. Available from: http://emc.medicines.org.uk/ [accessed August 2005].
18. Neotigason® Summary of Product Characteristics. Roche Products Ltd, 2004. Available from: http://emc.medicines.org.uk/ [accessed August 2005].
19. Zorac® Summary of Product Characteristics. Allergan Ltd, 2003. Available from: http://emc.medicines.org.uk/ [accessed August 2005].
20. Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151: 3-17.
21. Gottlieb AB. Psoriasis: Emerging therapeutic strategies. Nat Rev Drug Discov 2005; 4: 19-34.
22. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: Consensus conference. J Am Acad Dermatol 1998; 38: 478-485.
23. Tyring S, Poulin Y, Langley R, Gordon K, Jahreis A. A 2-year Phase 3 Study of Safety and Efficacy of Etanercept 50 mg Twice Weekly in patients with Psoriasis: 48-week Results. Presented at American Academy of Dermatology, July 20-24, 2005, Chicago, Illinois. Abstract P134.
24. Tyring S, Poulin Y, Langley R et al. Results of a 2-year Phase 3 Study of Safety and Efficacy of Etanercept 50 mg Twice weekly: 48-week PASI Results in Patients with Psoriasis. Presented at the European Academy of Dermatology and Venereology, October 12-15, 2005, London. Abstract 1534.
25. Mease PJ, Ritchlin CT, Martin RW et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004; 31: 1356-1361.
26. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004; 33: 283-288.
27. Goldsmith DR, Wagstaff AJ. Etanercept: A review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005; 6: 121-136.
28. Leonardi CL, Elewski B, Camisa C, Zitnik R. The efficacy and safety of etanercept in the retreatment of psoriasis after relapse (Abstract P568). J Acad Dermatol 2004; 50: 146.
29. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004; 363: 675-681.
30. Zhou H, Mayer PR, Wajdula J, Fatenejad S. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 2004; 44: 1235-1243.
31. Yamauchi PS, Lowe NJ, Koo S. Etanercept Therapy Allows Tapering of Methotrexate and Sustained Clinical Responses in Patients with Moderate to Severe Psoriasis. Presented at the American Academy of Dermatology, February 18-22, 2005, New Orleans, Louisiana. Abstract P2754.
32. Yamauchi PS, Lowe NJ, Koo S. Cessation of Cyclosporine Therapy by Treatment with Etanercept in Patients with Severe Psoriasis. Presented at the American Academy of Dermatology, February 18-22, 2005, New Orleans, Louisiana. Abstract P3.
33. Kazinski K, Joyce KM, Hodson D. The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of Hallopeau. J Drugs Dermatol 2005; 4: 360-364.
34. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: Nested cohort crossover study. Lancet 2001; 358: 1042-1045.
35. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: A 5-year cohort study. J Invest Dermatol 2003; 120: 211-216.
36. Gottlieb A, Gordon K, Wang A, Zitnik R. Withdrawal from etanercept after successful clinical response in psoriasis patients: Disease characteristics and the durability of treatment response (Abstract P566). J Acad Dermatol 2004; 50: 146.
37. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003; 30: 2315-2318.
38. Hansen KE, Hildebrand JP, Genovese MC et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 1098-1102.
39. Seigfried EC, Levy ML, Jahreis A, Paller AS. Etanercept in Children and Adolescents with Psoriasis. Presented at the American Academy of Dermatology, July 20-24, 2005, Chicago, Illanois. Abstract P81.
40. Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatology Guidelines for the Use of Biological Interventions in Psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
41. Kyle S, Chandler D, Griffiths CE et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005; 44: 390-397.